A Randomized Phase II Study of Durvalumab (MEDI4736) and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Trial Profile

A Randomized Phase II Study of Durvalumab (MEDI4736) and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Doxorubicin
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms MEDISARC
  • Most Recent Events

    • 27 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top